MindMed, Inc.


MindMed is a clinical-stage biopharmaceutical company dedicated to developing innovative, evidence-based treatments for brain health disorders using rigorous science. Their mission is to transform the treatment landscape for conditions such as Generalized Anxiety Disorder, Major Depressive Disorder, and Autism Spectrum Disorder through the therapeutic potential of psychedelics and novel compounds.

Industries

biotechnology
health-care
pharmaceutical

Nr. of Employees

medium (51-250)

MindMed, Inc.

New York, New York, United States, North America


Products

Orally disintegrating lysergide (LSD) tablet — clinical candidate for anxiety and depression

A pharmaceutically optimized orally disintegrating tablet formulation of lysergide intended for the treatment of generalized anxiety disorder and major depressive disorder; developed to provide rapid absorption and improved bioavailability with reduced gastrointestinal side effects.

R(-)-MDMA clinical candidate — investigational treatment for autism spectrum disorder

An enantiomer-enriched MDMA-related clinical candidate under preclinical and early clinical development, evaluated for effects on social functioning and communication in autism spectrum disorder.


Services

Clinical trial execution and management

Planning and running multicenter and decentralized clinical trials, including participant recruitment, site coordination, and safety monitoring.

Digital medicine study design and data collection

Design and conduct of digital studies to collect remote participant data and quantify psychotherapy and behavioral endpoints at scale.

Expanded access request evaluation

Policy-driven evaluation and management of expanded access (compassionate use) requests for investigational medications outside clinical trials.

Expertise Areas

  • Clinical trial management and operations
  • Digital medicine and decentralized studies
  • Formulation development for oral CNS delivery
  • Clinical pharmacology (PK/PD and dose-finding)
  • Show More (4)

Key Technologies

  • Orally disintegrating tablet (ODT) fast-dissolve formulation
  • Randomized double-blind placebo-controlled trial design
  • Open-label extension study design
  • Decentralized study platforms and digital data capture
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.